Singapore-Led Medtech Initiative Brings Breakthrough Artificial Heart Assist Device Technology into Indonesia, Southeast Asia’s Largest Healthcare Market

Millions of heart-failure patients in Indonesia may soon gain access to a new Chinese-developed artificial heart assist device designed for long-term support

Singapore – 20th November 2025. Indonesia.md, a Singapore-incorporated subsidiary of Borderless Healthcare Group, has secured exclusive rights to introduce a next-generation artificial heart assist device in Indonesia. Developed in Shenzhen, the device is the smallest and lightest of its kind currently available and is designed for long-term assistance for patients with severe heart failure.

Indonesia has more than 10 million heart-failure patients, with mortality rates above 34 percent. The country does not have a wide-reaching heart-transplant programme, and organ donation rates remain low within its majority Muslim population. These factors create a strong need for long-term mechanical circulatory support technologies.

The artificial heart assist device introduced through this initiative addresses these needs directly. It is more than 50 percent smaller than widely used United States devices and is built to fit Asian thoracic anatomy. Its engineering aims to reduce post-operative complications, and its lightweight, longer-lasting battery supports patient mobility and independence. The device can serve as a long-term therapy for patients who may not receive a donor heart.

Connecting Innovation Across Three Countries

In support of Singapore’s ambition to strengthen its role as Shenzhen’s innovation gateway into Southeast Asia, reaffirmed during the September 2025 meeting between Singapore Deputy Prime Minister Gan Kim Yong and Shenzhen Party Secretary Meng Liang, this initiative links Shenzhen’s medtech innovation with Singapore’s digital-health capabilities and Indonesia’s clinical needs.

Singapore as the Regional Medtech Accelerator

Indonesia.md will operate its Borderless Medical Cloud from Singapore to support collaboration across Indonesia, China, Singapore and other markets. The cloud platform will enable:

• Cross-border specialist input
• Pre-operative patient evaluation
• Post-operative monitoring and intervention
• Remote treatment-plan collaboration

To support patients after implantation, Indonesia.md will establish an agentic care network that includes caregivers, home-care nurses, physiotherapists, rehabilitation specialists, nutritionists and allied health professionals.

Singapore’s digital infrastructure, clinical governance systems and experience with cross-border medical services create a strong base for this initiative. This marks the first Singapore-led introduction of major Chinese cardiovascular technology into Indonesia and strengthens Singapore’s position as a regional platform for medtech deployment.

Clinical Leadership Across Three Countries

Dr Lim Chong Hee, who performed the first United States-made artificial heart assist device implantation in Asia, is one of the key contributors to this initiative. Dr Lim, now a founding stakeholder in Indonesia.md, recently underwent training with Dr Yan Efrata Sembiring, Vice-Chairman of the Indonesian Association of Thoracic, Cardiac and Vascular Surgeons. The training took place at Fuwai Hospital in Beijing, the world’s largest cardiac centre, and Wuhan Asia Heart Hospital, China’s largest private cardiac hospital.

A Scalable Model for Southeast Asia

The Indonesia.md initiative highlights Singapore’s role as a connector between China’s innovation ecosystem and Southeast Asia’s healthcare needs. Beginning with Indonesia, this model provides a scalable path for accelerating medtech adoption in the region. It supports Singapore’s growth as a hub for Chinese medtech investment, clinical collaboration and market expansion, contributing to the emergence of a MedTech 5.0 landscape built on connected medical knowledge, cloud-enabled services and agentic care networks.

About Indonesia.md

Indonesia.md is a Singapore-incorporated division of Borderless Healthcare Group, dedicated to transforming Indonesia’s healthcare ecosystem through medical-cloud infrastructure, advanced medtech integration, AI-enabled care, and cross-border collaboration. The platform supports clinical training, technology transfer, and next-generation patient care—bridging global innovation hubs with local healthcare systems.

About Borderless Healthcare Group

Borderless Healthcare Group (BHG) is a global ecosystem builder operating at the intersection of healthcare, medtech, telecommunications, and wellness. By integrating frontier technologies with leading clinical expertise, BHG accelerates the adoption of breakthrough health solutions across emerging markets, connecting innovators, clinicians, investors, and patients worldwide.

Media Contact

Lani Santiago
VP, Office of the Chairman at Borderless Healthcare Group
lani@borderlesshealthcare.com